Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

250%

5 of 2 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 4

2(40.0%)

5Total

Phase 1(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01552408Phase 1Completed

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

Role: lead

NCT01225146Phase 1Terminated

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

Role: lead

NCT01025232Phase 1Terminated

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

Role: lead

NCT01543568Phase 4Completed

Study for Recalcitrant Age Related Macular Degeneration

Role: lead

NCT00423189Phase 4Terminated

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

Role: lead

All 5 trials loaded